Shattuck Labs, Inc. STTK
5.44 USD -0.03 (-0.55%)
Nov 4, 2026, 10:15 AM EST
5.43 Day range 5.72
1.72 52-week range 8.33
- YTD
- +49.04%
- 1 year
- +181.87%
- Market cap
- 545.98M
- Revenue (ttm)
- 4.12M
- EPS (ttm)
- -0.47
- Shares out
- 47.74M
- Forward P/E
- -1.03
- YTD return
- +49.04%
- 1-year return
- +181.87%
- Volume
- 58.65K
- Avg volume
- 1.13M
- Open
- 5.61
- Previous close
- 5.47
- Day's range
- 5.43 – 5.72
- 52-week range
- 1.72 – 8.33
- Beta
- 1.86
- Price target
- 1.20 (-77.9%)
- Earnings date
- Aug 1, 2024
2Y +4.53 (+390.52%)
Key statistics
- Enterprise value
- -36.14M
- PEG ratio
- 0.00
- Price / sales
- 12.73
- Price / book
- 0.36
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 704.50%
- Free cash flow
- -31.85M
- Total cash
- 105.34M
- Total debt
- 3.82M
- Return on equity
- -68.48%
- Short % of float
- 6.90%
- 50-day average
- 1.23
- 200-day average
- 4.79
Analyst view
Price target (mean) 1.20
Ratings (0m) 5 2 buy · 3 hold · 0 sell
- Strong buy0
- Buy2
- Hold3
- Sell0
- Strong sell0
Next earnings
Aug 1, 2024
Expected Aug 1, 2024. Consensus EPS estimate -0.32348.
Financials — quick view
STTK Revenue — quarterly 0
STTK Net income — quarterly -15.15M
STTK EPS — quarterly -0.12
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.41 | -0.33 | +0.08 | +19.51% |
| Aug 1, 2024 | Jun 1, 2024 | -0.41 | -0.42 | -0.01 | -2.44% |
| Aug 1, 2024 | Jun 1, 2024 | -0.41 | — | — | — |
| May 2, 2024 | Mar 1, 2024 | -0.47 | -0.37 | +0.10 | +21.28% |
| May 2, 2024 | Mar 1, 2024 | -0.47 | — | — | — |
| Feb 29, 2024 | Dec 1, 2023 | -0.51 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | HC Wainwright & Co. | reit | — | Neutral |
| Nov 14, 2024 | Needham | reit | — | Hold |
| Oct 2, 2024 | Citigroup | down | Buy | Neutral |
| Oct 2, 2024 | Needham | down | Buy | Hold |
| Oct 1, 2024 | HC Wainwright & Co. | down | Buy | Neutral |
| Aug 27, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Shattuck Labs, Inc.
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- shattucklabs.com
News
UBS Initiates Coverage On Shattuck Labs with Buy Rating, Announces Price Target of $17 
Wedbush Maintains Outperform on Shattuck Labs, Raises Price Target to $14 
Abbott To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Friday - Needham Maintains Buy on Shattuck Labs, Raises Price Target to $19
Raymond James Initiates Coverage On Shattuck Labs with Strong Buy Rating, Announces Price Target of $18 
HC Wainwright & Co. Maintains Buy on Shattuck Labs, Lowers Price Target to $14 
Shattuck Labs Q2 EPS $(0.12) Misses $(0.10) Estimate 
This Shattuck Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday 
JP Morgan Initiates Coverage On Shattuck Labs with Overweight Rating, Announces Price Target of $10 - Leerink Partners Initiates Coverage On Shattuck Labs with Outperform Rating, Announces Price Target of $16
Your note
Sign in to keep a note on STTK — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BROUS TYLER | Director | Purchase | Jun 27, 2024 | 238,088 |
| DEYOUNG CASI | Officer | Stock Award(Grant) | Jan 9, 2024 | 91,497 |
| NEILL ANDREW R. | Chief Financial Officer | Stock Award(Grant) | Jan 9, 2024 | 173,446 |
| PANDITE ARUNDATHY N. | Officer | Stock Award(Grant) | Jan 9, 2024 | 219,280 |
| REDMILE GROUP, L.L.C. | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Dec 3, 2024 | 0 |
| SCHREIBER TAYLOR M.D., PH.D. | Chief Executive Officer | Purchase | Oct 6, 2024 | 2,681,750 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 15.00% | 7,159,090 | 7.87M | Sep 29, 2024 |
| Prosight Management, Lp | 11.90% | 5,678,726 | 6.25M | Sep 29, 2024 |
| Redmile Group, LLC | 11.76% | 5,615,489 | 6.18M | Sep 29, 2024 |
| Adage Capital Partners GP L.L.C. | 6.07% | 2,900,000 | 3.19M | Sep 29, 2024 |
| Blackrock Inc. | 5.47% | 2,613,294 | 2.87M | Sep 29, 2024 |
| Vanguard Group Inc | 5.03% | 2,401,909 | 2.64M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.75% | 1,314,560 | 1.45M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.14% | 1,021,505 | 1.12M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.45% | 692,870 | 762.16K | Sep 29, 2024 |
| Fidelity Series Small Cap Opportunities Fund | 1.30% | 622,739 | 685.01K | Aug 30, 2024 |
| Franklin Strategic Series-Franklin Biotechnology Discove | 1.06% | 505,804 | 556.38K | Jul 30, 2024 |
| Fidelity Small Cap Index Fund | 0.84% | 401,775 | 441.95K | Aug 30, 2024 |